Scand J Rheumatol. 2004;33(4):267-270. Spath M, Stratz T, Neeck G, Kotter I, Hammel B, Amberger C, Haus U, Farber L, Pongratz D, Muller W. Friedrich-Baur-Institute University of Munich.
Objective: To determine the efficacy of a serotonin receptor (5-HT(3)]]>) antagonist in the treatment of fibromyalgia (FM) in a prospective, randomized, double-blind, placebo-controlled, multicentre trial.
Subscribe to the World's Most Popular Newsletter (it's free!)
Methods: Twenty-one female patients (age 21-63 years) with FM according to the American College of Rheumatology classification criteria for FM were assigned randomly to either a placebo group or to receive a daily intravenous bolus injection of 5 mg tropisetron for 5 days.
Results: In patients receiving tropisetron, the visual analogue scale (VAS) score for pain decreased by 28.9 compared with a decrease of 6.8 in the placebo group [probability (p)=0.063; effect size: 0.794]. Similar results were obtained using a body diagram pain score as a secondary efficacy parameter: mean pain reduction was 27.2 in the tropisetron group, versus 2.8 in the placebo group (p=0.038; effect size: 0.902).
Conclusion: 5-HT(3)]]> receptor antagonists provide significant pain relief for a group of FM patients. PMID: 15370724 [PubMed – as supplied by publisher]